P2RY12 and atrial fibrillation: Dual antithrombotic treatment including a direct oral anticoagulant (DOAC) and single antiplatelet treatment with a P2Y12 inhibitor was associated with a significant increase in safety, as both total and major bleeding were significantly reduced using this approach in the recent PIONEER-AF Trial and RE-DUAL PCI Trial [2–3].